東曜藥業-B(01875.HK)與科興製藥(688136.SH)簽訂海外市場獨家商業化許可合作協議
格隆匯1月11日丨東曜藥業-B(01875.HK)發佈公吿，於2022年1月11日，公司全資附屬公司東曜藥業有限公司與科興製藥(688136.SH)簽訂海外市場獨家商業化許可合作協議，據此，科興製藥獲授予在除中國（包括中國大陸、香港、澳門和台灣地區）、歐盟（以2021年成員國為準）、英國、美國和日本以外所有國家和地區就樸欣汀（貝伐珠單抗注射液，擬使用英文商品名稱：Pusintin）的獨家商業化許可。
根據許可合作協議，作為授予獨家商業化許可的代價，蘇州東曜有權向科興製藥收取以下款項：(i)首付款及研發里程碑款，總計人民幣3,000萬元；(ii)銷售里程碑款，最高可達人民幣3.8億元，取決於樸欣汀在合作區域內的累計淨銷售額；及(iii)銷售提成，等於樸欣汀?在合作區域內的累計淨銷售額之低兩位數至高個位數百分比，按照遞減階梯式比例計算。
據悉，樸欣汀（貝伐珠單抗注射液，擬使用英文商品名稱：Pusintin）是由蘇州東曜自主開發的生物抗體藥物，於近期獲得中國國家藥品監督管理局的上市批准，用於治療晚期、轉移性或複發性非鱗狀非小細胞肺癌(nsNSCLC)和轉移性結直腸癌(mCRC)。樸欣汀是安維汀（Avastin）的生物類似藥，後者在中國已獲批用於治療nsNSCLC、mCRC、膠質母細胞瘤(GBM)、肝細胞癌(HCC)、卵巢癌和宮頸癌。樸欣汀採用集團自主開發的灌注－批式混合培養技術（PB-Hybrid技術）進行單抗藥物商業化生產，可通過25升WAVE生物反應器進行種子擴增，並直接擴展到2,000升規模的生物反應器，該技術相較於行業慣用技術，簡化了工藝流程、縮短生產週期、降低生產成本，更具成本優勢。
董事會認為，與科興製藥簽訂許可合作協議，有利於提升集團產品的國際競爭力，推動樸欣汀海外市場佈局，為新興國家癌症患者提供高品質且價格合理的國產藥物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
